ANI Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ANIP)

ANI Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANIP."

ANI Pharmaceuticals Inc (NASDAQ:ANIP) announced its earnings results on Wednesday, August, 7th. The specialty pharmaceutical company reported $1.44 EPS for the quarter, beating the consensus estimate of $1.18 by $0.26. The specialty pharmaceutical company had revenue of $54.36 million for the quarter, compared to the consensus estimate of $55.20 million. ANI Pharmaceuticals had a return on equity of 29.53% and a net margin of 8.14%. The company's revenue was up 15.0% on a year-over-year basis. During the same period last year, the business posted $1.13 EPS. View ANI Pharmaceuticals' Earnings History.

ANI Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for ANI Pharmaceuticals.

ANI Pharmaceuticals issued an update on its FY19 earnings guidance on Wednesday, August, 7th. The company provided earnings per share (EPS) guidance of $5.57-6.21 for the period, compared to the Thomson Reuters consensus EPS estimate of $6.01. The company issued revenue guidance of $220-226 million, compared to the consensus revenue estimate of $239.80 million.

4 equities research analysts have issued 12-month price targets for ANI Pharmaceuticals' shares. Their predictions range from $76.00 to $90.00. On average, they expect ANI Pharmaceuticals' share price to reach $84.25 in the next year. This suggests a possible upside of 16.3% from the stock's current price. View Analyst Price Targets for ANI Pharmaceuticals.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ANI Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ANI Pharmaceuticals.

News coverage about ANIP stock has trended somewhat negative on Monday, InfoTrie Sentiment reports. The research group identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. ANI Pharmaceuticals earned a coverage optimism score of -1.3 on InfoTrie's scale. They also assigned news coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for ANI Pharmaceuticals.

ANI Pharmaceuticals saw a decline in short interest in the month of August. As of August 31st, there was short interest totalling 1,393,100 shares, a decline of 6.7% from the July 31st total of 1,493,700 shares. Based on an average trading volume of 162,000 shares, the days-to-cover ratio is presently 8.6 days. Approximately 15.2% of the shares of the stock are sold short. View ANI Pharmaceuticals' Current Options Chain.

Some companies that are related to ANI Pharmaceuticals include FibroGen (FGEN), Evotec (EVTCY), Alkermes (ALKS), Global Blood Therapeutics (GBT), Taro Pharmaceutical Industries (TARO), BridgeBio Pharma (BBIO), Reata Pharmaceuticals (RETA), Arrowhead Pharmaceuticals (ARWR), HUTCHISON CHINA/S (HCM), Emergent Biosolutions (EBS), Myokardia (MYOK), Genmab A/S (GMAB), Arena Pharmaceuticals (ARNA), Ultragenyx Pharmaceutical (RARE) and Biohaven Pharmaceutical (BHVN).

Based on aggregate information from My MarketBeat watchlists, some companies that other ANI Pharmaceuticals investors own include Abraxas Petroleum (AXAS), Gilead Sciences (GILD), Teva Pharmaceutical Industries (TEVA), Broadcom (AVGO), Micron Technology (MU), Alibaba Group (BABA), Celgene (CELG), NVIDIA (NVDA), NXP Semiconductors (NXPI) and Cisco Systems (CSCO).

ANI Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (11.82%), Vanguard Group Inc. (4.68%), Nomura Holdings Inc. (3.12%), Nomura Holdings Inc. (3.10%), First Manhattan Co. (2.44%) and Renaissance Technologies LLC (2.39%). Company insiders that own ANI Pharmaceuticals stock include Arthur Przybyl, Daniel Raynor, David Nash, James G Marken, Meridian Venture Partners Ii L, Robert W Schrepfer, Thomas Haughey and Tracy Marshbanks. View Institutional Ownership Trends for ANI Pharmaceuticals.

ANIP stock was sold by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, Weiss Asset Management LP, Charles Schwab Investment Management Inc., Cadence Capital Management LLC, Panagora Asset Management Inc., Skandinaviska Enskilda Banken AB publ, Phocas Financial Corp. and Phocas Financial Corp.. Company insiders that have sold ANI Pharmaceuticals company stock in the last year include Arthur Przybyl, James G Marken, Meridian Venture Partners Ii L and Robert W Schrepfer. View Insider Buying and Selling for ANI Pharmaceuticals.

ANIP stock was acquired by a variety of institutional investors in the last quarter, including Invesco Ltd., Nomura Holdings Inc., Nomura Holdings Inc., Renaissance Technologies LLC, Nuveen Asset Management LLC, BlackRock Inc., THB Asset Management and First Manhattan Co.. Company insiders that have bought ANI Pharmaceuticals stock in the last two years include David Nash and Thomas Haughey. View Insider Buying and Selling for ANI Pharmaceuticals.

Shares of ANIP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ANIP stock can currently be purchased for approximately $72.42.

ANI Pharmaceuticals has a market capitalization of $876.28 million and generates $201.58 million in revenue each year. The specialty pharmaceutical company earns $15.49 million in net income (profit) each year or $4.61 on an earnings per share basis. ANI Pharmaceuticals employs 299 workers across the globe.View Additional Information About ANI Pharmaceuticals.

The official website for ANI Pharmaceuticals is http://www.anipharmaceuticals.com/.

ANI Pharmaceuticals' mailing address is 210 Main Street West, Baudette MN, 56623. The specialty pharmaceutical company can be reached via phone at 218-634-3500 or via email at [email protected]